You really cannot make this stuff up

Quote
Please, for the love of God, stop pretending to be a hard core salesperson because your in pharma. Your not!!!

I'm a pharma sales rep and yes, maybe back in the day, but now, please.

It was a great gig, but now, it is not. You may think your at the top, and without warning, you will be cut.

I'm working on plan b outside of pharma, forget because being a slave to Perry or KK.
 






anonymous said:
Quit the blame game! Sales people are expected to drive sales and meet/exceed goals. That is the job of a salesperson! If you don't do it, y'all get fired. I know this is somewhat revealing to snowflakes that believe a good try is just as good as meeting a sales quota. However, the only metric that matters in sales is $s!! If y'all don't like the job description then leave and look for another type of job. You are definitely not wired to be a salesperson.
Click to expand...


A.W. is that you?
 






anonymous said:
The NBU doesn't give a damn about xiidra or the obu or your launch. Your people are getting axed Bc leadership considers it a failure and it was stated at our meeting that it wasn't as successful of a launch as they had hoped. We've been here longer and know that mydayis will follow suit with xiidra Bc of the ineptitude of the people In Charge. If that offends you, I'm sorry but that's what the company is touting about the launch....its a failure . If you can't see that I feel sorry for you Bc you will end up blindsided and fired at some point. Don't trust this company for a second. Just business , nothing personal and just repeating facts
Click to expand...

I never said you DID care about OBU or Xiidra. We know that most of you don't and we don't blame you for it. NBU should've never been asked to do that. And for the record, the OBU people that were axed were let go because of performance and metrics. So yes, if you're not selling and moving the needle after 1 year, you might want to start looking for another opportunity. Snowflakes need not apply to sales positions.

As to my comment about Xiidra being the most successful launch in ophthalmic history, that wasn't SHIRE saying that. That came from one of the optometric journals a few months back. You say "don't trust this company" and complaining about leadership and how they're inept, yet you blindly trust them when that same NBU leadership (the same people that don't give a damn about Xiidra) tells you at a NBU meeting that the Xiidra launch has been a failure. Way to contradict yourself. "Don't listen to management. They're inept."........"Our management says Xiidra launch is a failure." Hmm.

If you have actually been making calls with ECPs (the actual person that matters in this equation), they'll tell you they love it and offering the 1st 30 days free when it works for many in as little as 2 weeks is the best launch strategy any company has ever done. "Brilliant" is the word that I've heard since August '16. The only negative I hear these days is the prior auths and no Med D coverage. Kind of expected though, so you get it where you can get it.

I'm not taking up for leadership, they botched quotas and the national goal for 2017 so if your leadership wants to say that Xiidra is failing because it's not hitting goal, whatever. How long have NBU reps not made quotas on Vyvanse because of unrealistic quotas? 2 years? Yet you won't hear anyone at OBU saying Vyvanse has been a failure the last 2 years.

It's not Xiidra's fault that we're not close to the national goal, nor is it 90% of the OBU reps' fault. The only failure for Xiidra in 2017 was the prediction that the market would grow another 12% which was factored into the IC plan. That hasn't happened. Market is still flat. Med D coverage will eventually get here and the growth will happen again.

But good luck with that mydayis launch.
 












What we can or cannot do, what we consider possible or impossible, is rarely a function of our true capability. It is more likely a function of our beliefs about who we are. Believe in OBU because we are doing a GREAT job!! A positive future is foreseen!
 
























anonymous said:
I never said you DID care about OBU or Xiidra. We know that most of you don't and we don't blame you for it. NBU should've never been asked to do that. And for the record, the OBU people that were axed were let go because of performance and metrics. So yes, if you're not selling and moving the needle after 1 year, you might want to start looking for another opportunity. Snowflakes need not apply to sales positions.

As to my comment about Xiidra being the most successful launch in ophthalmic history, that wasn't SHIRE saying that. That came from one of the optometric journals a few months back. You say "don't trust this company" and complaining about leadership and how they're inept, yet you blindly trust them when that same NBU leadership (the same people that don't give a damn about Xiidra) tells you at a NBU meeting that the Xiidra launch has been a failure. Way to contradict yourself. "Don't listen to management. They're inept."........"Our management says Xiidra launch is a failure." Hmm.

If you have actually been making calls with ECPs (the actual person that matters in this equation), they'll tell you they love it and offering the 1st 30 days free when it works for many in as little as 2 weeks is the best launch strategy any company has ever done. "Brilliant" is the word that I've heard since August '16. The only negative I hear these days is the prior auths and no Med D coverage. Kind of expected though, so you get it where you can get it.

I'm not taking up for leadership, they botched quotas and the national goal for 2017 so if your leadership wants to say that Xiidra is failing because it's not hitting goal, whatever. How long have NBU reps not made quotas on Vyvanse because of unrealistic quotas? 2 years? Yet you won't hear anyone at OBU saying Vyvanse has been a failure the last 2 years.

It's not Xiidra's fault that we're not close to the national goal, nor is it 90% of the OBU reps' fault. The only failure for Xiidra in 2017 was the prediction that the market would grow another 12% which was factored into the IC plan. That hasn't happened. Market is still flat. Med D coverage will eventually get here and the growth will happen again.

But good luck with that mydayis launch.
Click to expand...

You clearly didn't finished reading before you decided to go on a tirade. The post said mydayis will ALSO be a failure due to inept management. So never trust this company.

No one over here blindly trusts the NBU management . They're the biggest joke in pharma and we dont get paid anymore . Most of us are trying to get out and so should everyone else, including you. But calm down a little before jumping to conclusions.

The NBU doesn't fault your sales force for failure . We know all about unrealistic goals and expectations and have been experiencing them long before the xiidra launch

This place is a dumpster fire
 






anonymous said:
You clearly didn't finished reading before you decided to go on a tirade. The post said mydayis will ALSO be a failure due to inept management. So never trust this company.

No one over here blindly trusts the NBU management . They're the biggest joke in pharma and we dont get paid anymore . Most of us are trying to get out and so should everyone else, including you. But calm down a little before jumping to conclusions.

The NBU doesn't fault your sales force for failure . We know all about unrealistic goals and expectations and have been experiencing them long before the xiidra launch

This place is a dumpster fire
Click to expand...
NBU Sales is a JOKE. All you do is work the sample closet! Last time you detailed a doc?!?!?
 


















anonymous said:
The NBU doesn't sample unlike the OBU. We have zero ability to get signatures : Clearly this must be a typeo
Click to expand...

not a typo. its some bored troll that keeps showing up on all the shire threads lately. clearly, said troll doesnt work for the company as he/she just blows smoke (full of incorrect info too).
 


















anonymous said:
Xiidra was named the best launched drug in ophthalmic history, so very far from a botch job. Has the growth flattened out? Yes, won't argue with you there but it's only because refills are tough with PAs and no Med D coverage. Notice how it STILL hasn't grown any since NBU came on board to "rescue" OBU so just stop with the OBU vs NBU divisiveness and stay in your lane.

The things we have in common at OBU and NBU:
1) We both are great at what we do.
2) The expectations for growth and quotas for our products are unattainable.
3) Many are looking to leave for better opportunities.
4) We both share the same leadership.
Click to expand...

Just out of curiosity, who exactly named Xiidra the best launched drug in ophthalmic history?
 






























Top Bottom
Back
Quote